EfficacyObicetrapib treatment led to 77% of patients reaching the goal LDL-C reduction level of <100mg/dL compared to placebo of 40%.
Market PotentialIf successful, obi is expected to generate blockbuster sales by addressing unmet needs in the ~30MM patients unable to meet LDL-C targets with current therapies.
Safety ProfileObicetrapib demonstrated significant improvements in non-HDL-C, Lp(a), ApoB, and HDL-C, along with an excellent safety profile comparable to placebo.